S&P 500   4,002.87 (+1.30%)
DOW   32,560.60 (+0.98%)
QQQ   310.34 (+1.43%)
AAPL   159.28 (+1.19%)
MSFT   273.78 (+0.57%)
META   202.16 (+2.20%)
GOOGL   104.92 (+3.66%)
AMZN   100.61 (+2.97%)
TSLA   197.58 (+7.82%)
NVDA   261.99 (+1.15%)
NIO   9.27 (+5.94%)
BABA   83.70 (+3.33%)
AMD   95.93 (-0.91%)
T   18.54 (+0.27%)
F   11.72 (+4.83%)
MU   58.63 (+1.72%)
CGC   1.97 (+5.91%)
GE   92.18 (+2.51%)
DIS   96.54 (+2.46%)
AMC   4.41 (+3.28%)
PFE   40.66 (-0.37%)
PYPL   76.72 (+4.79%)
NFLX   305.79 (+0.22%)
S&P 500   4,002.87 (+1.30%)
DOW   32,560.60 (+0.98%)
QQQ   310.34 (+1.43%)
AAPL   159.28 (+1.19%)
MSFT   273.78 (+0.57%)
META   202.16 (+2.20%)
GOOGL   104.92 (+3.66%)
AMZN   100.61 (+2.97%)
TSLA   197.58 (+7.82%)
NVDA   261.99 (+1.15%)
NIO   9.27 (+5.94%)
BABA   83.70 (+3.33%)
AMD   95.93 (-0.91%)
T   18.54 (+0.27%)
F   11.72 (+4.83%)
MU   58.63 (+1.72%)
CGC   1.97 (+5.91%)
GE   92.18 (+2.51%)
DIS   96.54 (+2.46%)
AMC   4.41 (+3.28%)
PFE   40.66 (-0.37%)
PYPL   76.72 (+4.79%)
NFLX   305.79 (+0.22%)
S&P 500   4,002.87 (+1.30%)
DOW   32,560.60 (+0.98%)
QQQ   310.34 (+1.43%)
AAPL   159.28 (+1.19%)
MSFT   273.78 (+0.57%)
META   202.16 (+2.20%)
GOOGL   104.92 (+3.66%)
AMZN   100.61 (+2.97%)
TSLA   197.58 (+7.82%)
NVDA   261.99 (+1.15%)
NIO   9.27 (+5.94%)
BABA   83.70 (+3.33%)
AMD   95.93 (-0.91%)
T   18.54 (+0.27%)
F   11.72 (+4.83%)
MU   58.63 (+1.72%)
CGC   1.97 (+5.91%)
GE   92.18 (+2.51%)
DIS   96.54 (+2.46%)
AMC   4.41 (+3.28%)
PFE   40.66 (-0.37%)
PYPL   76.72 (+4.79%)
NFLX   305.79 (+0.22%)
S&P 500   4,002.87 (+1.30%)
DOW   32,560.60 (+0.98%)
QQQ   310.34 (+1.43%)
AAPL   159.28 (+1.19%)
MSFT   273.78 (+0.57%)
META   202.16 (+2.20%)
GOOGL   104.92 (+3.66%)
AMZN   100.61 (+2.97%)
TSLA   197.58 (+7.82%)
NVDA   261.99 (+1.15%)
NIO   9.27 (+5.94%)
BABA   83.70 (+3.33%)
AMD   95.93 (-0.91%)
T   18.54 (+0.27%)
F   11.72 (+4.83%)
MU   58.63 (+1.72%)
CGC   1.97 (+5.91%)
GE   92.18 (+2.51%)
DIS   96.54 (+2.46%)
AMC   4.41 (+3.28%)
PFE   40.66 (-0.37%)
PYPL   76.72 (+4.79%)
NFLX   305.79 (+0.22%)
NASDAQ:SPNE

SeaSpine - SPNE Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$8.43
$9.67
50-Day Range
$7.03
$9.54
52-Week Range
$5.48
$14.23
Volume
1.16 million shs
Average Volume
822,700 shs
Market Capitalization
$354.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.69

SeaSpine MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
54.0% Upside
$14.69 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$30,288 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.62) to ($1.30) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

601st out of 988 stocks

Surgical & Medical Instruments Industry

61st out of 101 stocks


SPNE stock logo

About SeaSpine (NASDAQ:SPNE) Stock

As of January 4, 2023, SeaSpine Holdings Corporation was acquired by Orthofix Medical Inc. SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. It offers orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. The company's orthobiologics products include demineralized bone matrix (DBM), collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to improve bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. It also offers orthobiologics products in various forms, such as fibers, putties, pastes, strips, and DBM. In addition, the company offers implant products for spinal decompression, alignment, stabilization, and image-guided surgical solutions, as well as a surgical navigation system used to facilitate fusion in degenerative, minimally invasive, and complex spinal deformity procedures throughout the lumbar, thoracic, and cervical regions of the spine. SeaSpine Holdings Corporation was incorporated in 2015 and is headquartered in Carlsbad, California.

Receive SPNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SeaSpine and its competitors with MarketBeat's FREE daily newsletter.

SPNE Stock News Headlines

Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
Adele reveals ‘painful’ spinal issues
See More Headlines
Receive SPNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SeaSpine and its competitors with MarketBeat's FREE daily newsletter.

SPNE Company Calendar

Last Earnings
10/28/2021
Today
3/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SPNE
Fax
N/A
Employees
523
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.69
High Stock Price Forecast
$21.00
Low Stock Price Forecast
$6.75
Forecasted Upside/Downside
+54.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-54,350,000.00
Pretax Margin
-28.83%

Debt

Sales & Book Value

Annual Sales
$191.45 million
Book Value
$8.57 per share

Miscellaneous

Free Float
33,736,000
Market Cap
$354.92 million
Optionable
Optionable
Beta
1.31

Key Executives

  • Mr. Keith C. Valentine (Age 54)
    Pres, CEO & Director
    Comp: $977.29k
  • Mr. John J. Bostjancic (Age 51)
    Sr. VP, CFO, COO & Treasurer
    Comp: $556.62k
  • Dr. Beau Standish P.Eng. (Age 42)
    Ph.D., Pres of Enabling Technologies
    Comp: $345.15k
  • Dr. Frank Vizesi
    Chief Scientific Officer
  • Carrie Mendivil
    Head of Investor Relations
  • Mr. Patrick L. Keran J.D. (Age 50)
    Sr. VP, Gen. Counsel & Sec.
  • Mr. John J. Winge (Age 55)
    VP of Sales
  • Ms. Hollis Winkler (Age 47)
    Sr. VP of HR
  • Mr. Tyler P. Lipschultz (Age 55)
    Sr. VP of Orthobiologics & Bus. Devel.
  • Mr. Dennis L. Cirino (Age 52)
    Sr. VP of Global Spinal Systems













SPNE Stock - Frequently Asked Questions

Should I buy or sell SeaSpine stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SeaSpine in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SPNE shares.
View SPNE analyst ratings
or view top-rated stocks.

What is SeaSpine's stock price forecast for 2023?

3 equities research analysts have issued twelve-month price objectives for SeaSpine's stock. Their SPNE share price forecasts range from $6.75 to $21.00. On average, they predict the company's stock price to reach $14.69 in the next twelve months. This suggests a possible upside of 54.0% from the stock's current price.
View analysts price targets for SPNE
or view top-rated stocks among Wall Street analysts.

How were SeaSpine's earnings last quarter?

SeaSpine Holdings Co. (NASDAQ:SPNE) posted its earnings results on Thursday, October, 28th. The medical equipment provider reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.31) by $0.17. The medical equipment provider earned $46.45 million during the quarter, compared to analyst estimates of $45.66 million. SeaSpine had a negative net margin of 28.22% and a negative trailing twelve-month return on equity of 22.16%. The company's revenue was up 7.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.24) earnings per share.

What ETF holds SeaSpine's stock ?

AltShares Merger Arbitrage ETF holds 48,619 shares of SPNE stock, representing 0.43% of its portfolio.

What guidance has SeaSpine issued on next quarter's earnings?

SeaSpine updated its fourth quarter 2022 earnings guidance on Tuesday, January, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $63.20 million-$63.70 million, compared to the consensus revenue estimate of $63.31 million.

What is Keith Valentine's approval rating as SeaSpine's CEO?

23 employees have rated SeaSpine Chief Executive Officer Keith Valentine on Glassdoor.com. Keith Valentine has an approval rating of 79% among the company's employees.

What other stocks do shareholders of SeaSpine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SeaSpine investors own include AbbVie (ABBV), Corbus Pharmaceuticals (CRBP), Gilead Sciences (GILD), Kura Oncology (KURA), Recro Pharma (REPH), Rigel Pharmaceuticals (RIGL), Spectrum Pharmaceuticals (SPPI), ViewRay (VRAY), Verastem (VSTM) and Akorn (AKRX).

What is SeaSpine's stock symbol?

SeaSpine trades on the NASDAQ under the ticker symbol "SPNE."

Who are SeaSpine's major shareholders?

SeaSpine's stock is owned by many different institutional and retail investors. Top institutional investors include First Light Asset Management LLC (18.49%), AWM Investment Company Inc. (2.96%), Emerald Advisers LLC (2.33%), Dimensional Fund Advisors LP (1.88%), JPMorgan Chase & Co. (1.62%) and Bardin Hill Management Partners LP (1.50%). Insiders that own company stock include Beau Standish, John B Henneman III, Renee Gaeta, Richard E Caruso and Shweta Maniar.
View institutional ownership trends
.

What is SeaSpine's stock price today?

One share of SPNE stock can currently be purchased for approximately $9.54.

How much money does SeaSpine make?

SeaSpine (NASDAQ:SPNE) has a market capitalization of $354.92 million and generates $191.45 million in revenue each year. The medical equipment provider earns $-54,350,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis.

How many employees does SeaSpine have?

The company employs 523 workers across the globe.

How can I contact SeaSpine?

SeaSpine's mailing address is 5770 ARMADA DRIVE, CARLSBAD CA, 92008. The official website for the company is www.seaspine.com. The medical equipment provider can be reached via phone at (760) 727-8399 or via email at ir@seaspine.com.

This page (NASDAQ:SPNE) was last updated on 3/21/2023 by MarketBeat.com Staff